Program

HomeProgram ▶ Non-CME Symposia
Non-CME Symposia

Sunday, May 19, 2019

Fairmont Dallas

International Ballroom

06:30 PM - 09:30 PM


An Add-on Maintenance Treatment Option for Patients with Moderate-to-Severe Uncontrolled Asthma Driven by Type 2 Inflammation

The session will begin with a presentation of an add-on maintenance treatment option for certain patients with moderate-to-severe asthma. The presentation will cover the approved indication, mechanism of action and supporting clinical data. Following the session, our moderators will lead an interactive discussion of several hypothetical patient cases for whom this treatment option may be appropriate. Our discussion will focus on rationales for considering this treatment option for heterogeneous patients with distinct clinical characteristics suggesting that Type 2 inflammation contributes to their uncontrolled asthma.

Speakers: Geoffrey Chupp MD Yale Center for Asthma and Airway Disease; Laren Tan MD Loma Linda University Medical Center

Company: Sanofi Genzyme and Regeneron


Regency Ballroom

06:30 PM - 09:30 PM


Bronchiectasis: Emerging Trends and Unmet Needs (Open to U.S. attendees only)

Emerging evidence shows that non-cystic fibrosis bronchiectasis (NCFB) is more common than previously thought and is viewed as a severe comorbidity of COPD. Appropriate diagnosis and treatment are key to improving outcomes and quality of life, and to helping reduce health care costs. In this non-CME educational symposium, global NCFB experts describe why awareness of the condition is growing, how to accurately identify patients with NCFB, and how to address symptoms within the framework of “treatable traits.” They will present the latest research, clinical guidelines and actionable information related to this under-recognized but critically important pulmonary condition.

Speakers: Michael Polkey, MD, Royal Brompton Hospital, London UK; Timothy Aksamit, MD, Mayo Clinic, Rochester, MN; James Chalmers, MBChB, PhD, University of Dundee and Ninewells Hospital and Medical School, Dundee UK; Tara Barto, MD, Baylor College of Medicine, Houston, TX

Company: RespirTech, a Philips company


Hyatt Regency Dallas

Landmark Ballroom A

06:30 PM - 09:30 PM


Nasal High Flow in the Critical Care Setting

This session highlights advances in improved care of respiratory failure and the clinical outcomes in critical care and emergency medicine utilizing nasal high flow therapy. Nasal high flow is optimal humidified respiratory support at up to 60L/min with the AIRVO2 to provide reduction of dead space, delivery of a dynamic positive airway pressure, airway hydration, patient comfort, and supplemental oxygen. These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels and improved mucus clearance. Clinical studies demonstrate that nasal high flow therapy may reduce escalation of care, reduce mortality rates and improve symptomatic relief.

Speakers: Tomaso Mauri MD PhD University of Milan; Nicholas Hill MD Tufts University; Stanislav Tatkov MD, PHD Fisher & Paykel Healthcare

Company: Fisher & Paykel Healthcare


Landmark Ballroom B

06:30 PM - 09:30 PM


Uncontrolled Obstructive Airway Diseases: Treatment and Stepwise Management Approaches to Severe Asthma and Exacerbations in Chronic Obstructive Pulmonary Disease (COPD)

Learn treatment and early management approaches to severe asthma and exacerbations in COPD.  A national panel of experts will discuss the burden and impact of severe asthma as well as the challenges associated with overreliance on oral corticosteroids (OCS). Also, the importance of COPD exacerbations and their impact on patients in real world clinical practice will be discussed as well as the need to help prevent future exacerbations.

Speakers: Nicola Hanania MD ; Gene Bleecker MD ; Gary Ferguson MD

Company: AstraZeneca


Landmark Ballroom C

06:30 PM - 09:30 PM


A Disease-State Presentation: Exploring Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare vasculitis that often involves the respiratory tract, affects small to medium vessels, and is associated with asthma and eosinophilia. EGPA is difficult to diagnose and manage due to its rarity and complexity. Early recognition is critical to avoid organ damage. This educational session will review the pathogenesis, clinical manifestations, classification criteria, diagnosis and prognosis of EGPA.

Speaker: Michael Wechsler MD, MMSc

Company: GlaxoSmithKline


Marsalis Exhibit Hall A

06:30 PM - 09:30 PM


Systemic Sclerosis–Associated Interstitial Lung Disease: Expert Insights on Early Diagnosis and Optimal Management

Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Interstitial lung disease (ILD) occurs in the majority of patients with SSc and is now the number one cause of death in these patients. Treatment for SSc-associated ILD has historically been limited; however, novel therapies have shown promise in clinical trials. Through a live, non-CME MasterClass held during the American Thoracic Society (ATS) International Conference on May 19, 2019, in Dallas, Texas, a panel of expert faculty will offer insight to help clinicians achieve a greater understanding into the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence with respect to emerging therapies. 

Link to Register: PeerView.com/ILD19Dallas

Speakers: Marilyn K. Glassberg MD University of Miami School of Medicine; Aryeh Fischer MD University of Colorado School of Medicine; Kristin B. Highland MD, MSCR Cleveland Clinic

Company: This non-CME educational program is sponsored by PVI, PeerView Institute for Medical Education, and supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


Sheraton Dallas Hotel

Lone Star Ballroom A2-A4

06:30 PM - 09:30 PM


A Multidisciplinary Case-study Approach: From Recognition to Progression of Fibrosing ILDs

This symposium will enlist an expert multidisciplinary panel detailing various clinical presentations of progressive fibrosing interstitial lung diseases. Case studies will be utilized and will focus on initial clinical presentations of various fibrotic ILDs, disease progression over time, and how identifying the progressive phenotype of ILD-associated diseases will help guide patient care decisions. This interactive panel discussion will demonstrate the importance of multidisciplinary discussions in resolving diagnostic challenges.

Speakers: Gregory P. Cosgrove MD, FCCP National Jewish Health; Flavia V. Castelino MD Massachusetts General Hospital; Harvard Medical School; Lida Hariri MD, PhD Massachusetts General Hospital; Harvard Medical School; Geoffrey D. Rubin MD, MBA, FACR Duke University School of Medicine

Company: Boehringer Ingelheim Pharmaceuticals, Inc.


Lone Star Ballroom B

06:30 PM - 09:30 PM


In Pursuit of the Leaking Lymph: Nonmalignant Thoracic Lymphatic Disorders

Experts will discuss classification of pulmonary lymphatic disorders, and evaluate new imaging and therapeutic approaches for the differentiation and treatment of these disorders. They will also assess pulmonary involvement in patients with lymphatic malformations. Interactive clinical case presentations will provide scientific pearls for integrating diagnostic and therapeutic algorithms into your practice.

Speakers: Maxim Itkin MD, FSIR Perelman School of Medicine, University of Pennsylvania ; Bruce K. Rubin MD, MEngr, MBA, FRCPC Virginia Commonwealth University School of Medicine and Children's Hospital of Richmond at VCU; Christopher Towe MD Cincinnati Children's Hospital Medical Center

Company: A non-CME educational program sponsored by Vindico Medical Education and supported by a Grant from Guerbet, LLC open to all ATS 2019 International Conference attendees.


Lone Star Ballroom C2-C4

06:30 PM - 09:30 PM


Exploring Idiopathic Pulmonary Fibrosis (IPF) with the Experts: A Multidisciplinary Program on the Diagnosis, Treatment, and Management of IPF (Open to U.S. attendees only)

Join us for an innovative symposium led by a multidisciplinary team of idiopathic
pulmonary fibrosis (IPF) experts. In this interactive and case-based program, attendees
will explore such topics as the importance of prompt diagnosis, the potential benefits
and risks of treating patients with an FDA-approved IPF-specific therapy, and the steps
for initiating and maintaining a comprehensive management plan.

Speakers: Anne Whitney Brown MD Virginia Commonwealth University School of Medicine Inova Fairfax Campus Falls Church, VA; Cedric Jamie Rutland MD University of California, Riverside School of Medicine Riverside, CA; Jubal Watts, Jr. MD Radiology of Huntsville Huntsville, AL

Company: Genentech, A Member of the Roche Group


Tuesday, May 21, 2019

Fairmont Dallas

International Ballroom

06:30 PM - 09:30 PM


U.S. Presidents with Severe Asthma: Endotypes and Precision Medicine

This activity will delve into the lives of US Presidents with asthma, to draw a contrast between treatment approaches of the past and current and emerging therapies that target specific disease mechanisms. We’ll summarize mechanisms of action as well as key efficacy and safety data for cytokine antagonists being used or investigated for severe asthma treatment. The information learned will then be applied, using case scenarios, in selecting personalized treatments based on asthma phenotypes and endotypes. This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. Register at: www.pilotforpulmonary.org/asthma19

Speakers: Tara Carr MD The University of Arizona Health Sciences; Nicola Hanania MD Baylor College of Medicine; Linda Rogers MD Icahn School of Medicine at Mount Sinai

Company: The France Foundation, supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals


Regency Ballroom

06:30 PM - 09:30 PM


The Current State of Idiopathic Pulmonary Fibrosis

This symposium will enlist two expert pulmonologists presenting information on idiopathic pulmonary fibrosis (IPF). Current knowledge regarding IPF, including the updated 2018 ATS/ERS/JRS/ALAT diagnostic guidelines, as well as recommendations for use of multidisciplinary discussions in patient diagnosis, will be reviewed.

Speakers: Justin Oldham MD, MS University of California, Davis; Mark Hamblin MD, FCCP University of Kansas Hospital

Company: Boehringer Ingelheim Pharmaceuticals, Inc.


Hyatt Regency Dallas

Landmark Ballroom A

06:30 PM - 09:30 PM


Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease

Learn what you’re missing about alpha-1 antitrypsin deficiency (AATD) lung disease! Interact with world-renowned experts including Drs. Sandhaus, Stocks, Campos and a live AATD patient during this dynamic evidence-based symposium. We’ll discuss several AATD patient types, such as high-risk genotype and low FEV1 as well as diagnostic considerations and therapeutic interventions including augmentation therapy.  In addition, you can submit your challenging AATD clinical cases and get expert opinions for management.  

This symposium is organized by RMEI Medical Education and supported by independent educational grants from Shire (now part of Takeda), Grifols, and CSL Behring.

Speakers: Robert A. Sandhaus MD, PhD, FCCP National Jewish Medical and Research Center ; Michael A. Campos MD University of Miami School of Medicine; James M. Stocks MD University of Texas Health Science Center at Tyler

Company: RMEI Medical Education


Landmark Ballroom C

06:30 PM - 09:30 PM


The Changing Landscape of Nontuberculous Mycobacterial Lung Disease (NTM-LD): A 3D View of Pathogenesis, Diagnosis and Management

This engaging 3D Satellite Symposium offers a unique learning opportunity investigating NTM-LD.  Worldwide prevalence has been increasing, with pervasive impacts exhibited among chronic and structural lung disease, aging and immunocompromised populations. Through evidence-based didactics, case-based learning and 3D animation, complexities of diagnosis and management will be explored for m. avium complex (MAC) and m. abscessus with the aim to: 

- Review microbiology, pathogenesis and environmental aspects of NTM.
- Summarize recent data on NTM epidemiology and risk factors.
- Describe treatment goal personalization methodologies.
- Assess drug-related adverse event prevention strategies.
- Evaluate established and emerging therapy clinical data.

Speakers: Charles L. Daley MD National Jewish Health; Kevin Winthrop MD, MPH Oregon Health & Science University

Company: Insmed Incorporated


Marsalis Exhibit Hall A

06:30 PM - 09:30 PM


Are We There Yet? Tips to Better IPF Management

Our faculty will engage learners in interactive “What would YOU do?” case-based questions and demonstrate the positive impact of shared decision making. It will included a short patient testimonial as to the impact and burden that IPF has had on them and how shared decision making made a positive difference in their care plan, treatment adherence, and quality of life. Register at https://www.pilotforpulmonary.org/ipf19

Speakers: Marilyn K. Glassberg MD Miller School of Medicine, University of Miami, Miami, Florida; Lisa H. Lancaster MD Vanderbilt University Medical Center, Nashville, Tennessee; Fernando J. Martinez MD, MS New York Presbyterian Hospital/ Weill Cornell Medical Center, New York, New York

Company: The France Foundation, supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc and Genentech


Reunion Ballrom GH

06:30 PM - 09:30 PM


The Severe Asthma Challenge

Test your knowledge of allergic asthma! Doctors William J. Calhoun and Reynold A. Panettieri Jr will host a live game-show—The Severe Asthma Challenge—where dinner attendees will have the opportunity to compete against their peers. The highest-scoring contestants from the first round will move on to compete on the main stage in the final round. Questions will focus on the following topics: asthma phenotypes and endotypes, the role of biomarkers in asthma, and the role of immunoglobulin E (IgE) in allergic asthma.

Speakers: William J. Calhoun MD University of Texas Medical Branch, Galveston, TX; Reynold A. Panettieri, Jr MD Rutgers Institute for Translational Medicine, New Brunswick, NJ

Company: Genentech, Inc. and Novartis Pharmaceuticals Corporation


Sheraton Dallas Hotel

Lone Star Ballroom A2-A4

06:30 PM - 09:30 PM


Paving the Way in Fibrotic Lung Disease: Expanding Applications for Existing Therapies

Expert faculty will discuss progressive fibrosing interstitial lung disease, providing guidance on its timely and accurate identification; they will also evaluate the expanding applications for current idiopathic pulmonary fibrosis therapies in other fibrotic lung diseases. Case presentations will provide scientific pearls for the integration of diagnostic and therapeutic algorithms into clinical practice.

Speakers: Amy L. Olson MD, MSPH National Jewish Health ; Kevin R. Flaherty MD, MS University of Michigan ; Steven D. Nathan MD Inova Fairfax Hospital and Virginia Commonwealth University - Inova Fairfax Campus

Company: A non-CME educational program sponsored by Vindico Medical Education and supported by a Grant from Boehringer Ingelheim Pharmaceuticals, Inc. open to all ATS 2019 International Conference attendees.